Skip to main content
. 2023 Feb 13;19(3):513–522. doi: 10.1007/s11302-023-09925-2

Table 2.

Best Observed responses (RECIST 1.1) by treatment arm in the phase II trial [52]

Response, n (%) Namodenoson
n = 34
Placebo
n = 21
CR 0 (0.0%) 0 (0.0%)
PR 3 (8.8%) 0 (0.0%)
SD 17 (50.0%) 10 (47.6%)
PD 14 (41.2%) 11 (52.4%)

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease